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A History of Pluripotent Cells 
 
After the discovery of the first stem cells by Drs. Ernest 
McCulloch and James Till, research with stem cells has 
grown exponentially.  While McCulloch and Till were 
responsible for discovering multipotent stem cells in bone 
marrow – which are capable of differentiating into platelets, 
red blood cells, or white blood cells – we now know many 
characteristics of embryonic stem cells (ESCs), which were 
first isolated in 1981 (Yamanaka, 2009).  During embryonic 
development, ESCs can be harvested from the inner cell 
mass of blastocysts prior to implantation (Nelson, et al., 
2009; Yamanaka, 2009; Gearhart, et al., 2007).  ESCs can 
develop into tissues from all three germ layers – the 
mesoderm, ectoderm, and endoderm – meaning they are 
pluripotent (Nelson, et al., 2009; Gearhart, et al., 2007).  This 
characteristic makes them very appealing for disease 
treatments that require propagation of phenotypically specific 
cells.   
 Many of the genes and transcription factors that 
either maintain or are correlated with ESC pluripotency have 
recently been identified.  The transcription factors Oct3/4, 
Sox2, and E1A are known to maintain the undifferentiated 
state of mammalian ESCs through the fibroblast growth 
factor-4 (FGF-4), Wnt, and transforming growth factor-β 
(TGF-β) pathways (Nelson, et al., 2009).  Human ESC 
pluripotency is dependent upon the Src family of tyrosine 
phosphatases, Oct3/4, Nanog, the proteoglycans TRA-1-
60/81 and GCTM-2, and the embryonic antigens SSEA-3 
and SSEA-4 (Nelson, et al., 2009).  These factors and others 
that maintain ESC pluripotency can serve as ESC cell 
markers in culture.  ESCs also have a specific morphology 
which makes their identification in culture easy.  For 
instance, ESC nuclei are generally large compared to the 
cytoplasm, and the surfaces of ESCs are generally smooth 
and rounded (Nelson, et al., 2009; Takahashi & Yamanaka, 
2006). 
 Since ESCs are pluripotent, easily maintained in 
culture, have a unique gene expression, and specific 
morphology, they are very useful in the laboratory.  A report 
by Cho, et al. found that ESCs can be differentiated into 
functional neurons and used to treat an animal model of 
Parkinson’s disease (Rolletschek & Wobus, 2009).  In other 
applications, ESCs have successfully been differentiated into 
cells that produce insulin in diabetic animals (Rolletschek & 
Wobus, 2009).  While reports similar to these demonstrate 
the successful applications of ESCs in animal model disease 
treatments, there are limitations to the usefulness of ESCs. 
 The most prominent limitation of ESC research is 
the ethical dilemma that surrounds them (Okita, Ichisaka, & 
Yamanaka, 2007).  Many religious groups do not approve of 
the destruction of embryos that is necessary to harvest 
ESCs, thus causing researchers to look for alternative 
methods of stem cell research (Rolletshcek & Wobus, 2009).  
If ethics were not a large enough obstacle, tissues and 
organs generated from ESCs for transplantation have a high  
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possibility of being rejected by recipient immune systems 
(Nelson, et al., 2009; Okita, Ichisaka, & Yamanaka, 2007; 
Takahashi & Yamanaka, 2006).  The blastocysts that ESCs 
are harvested from are not genetically similar to graft 
recipients and are therefore predisposed to attack by the 
patient’s immune system.  To avoid these problems some 
researchers have attempted to use adult stem cells for 
similar applications.  However, adult stem cells are typically 
difficult to isolate, do not culture well in the lab, and are only 
multipotent – i.e. they have limited differentiation abilities. 
Scientists have therefore focused their energies 
on creating pluripotent stem cells from somatic cells or 
reversing cell differentiation through nuclear reprogramming.  
The first attempts to induce pluripotency were through 
somatic cell-ESC fusion and somatic cell nuclear transfer.  
Somatic cell-ESC fusion – in which the inner contents of a 
somatic cell and an ESC are combined – does not avoid the 
use of ESCs or the risk of graft host rejection.  Furthermore, 
the cells generated by somatic cell-ESC fusion are tetraploid 
and of little use in practical applications (Gearhart, et al., 
2007).  To induce pluripotency by somatic cell nuclear 
transfer, researchers remove the nuclear contents of a 
somatic cell and insert them into oocytes (Glover, 2008).  
Unknown factors in the cytoplasm of the receiving oocytes 
cause the somatic cell to exhibit pluripotent characteristics 
(Glover, 2008). However, this method requires donor 
oocytes, which are not always easy to obtain (Glover, 2008).  
Also, the efficiency of this process is very low and attempts 
to obtain pluripotent cells using human somatic cells have 
been unsuccessful (Nelson, et al., 2009; Glover, 2008; 
Gearhart, et al., 2007).  While neither the methods for 
somatic cell-ESC fusion nor somatic cell nuclear transfer 
were successful at overcoming the limitations of ESCs, they 
paved the road for the first induced pluripotent stem cells. 
 In 1999, Dr. Shinya Yamanaka began researching 
a way to produce pluripotent cells without the use of oocytes 
and, most importantly, without the use of ESCs.  His 
knowledge of somatic cell nuclear transfer and ESC-somatic 
cell fusion let Dr. Yamanaka know that it is possible to create 
pluripotent cells from previously differentiated cells.  
However, the methods for both nuclear transfer and cell 
fusion are difficult to perform and neither oocytes nor ESCs 
are readily available.  Many researchers, including Dr. 
Yamanaka, were postulating that ESCs and oocytes must 
contain certain similar factors that can reprogram somatic 
cell nuclei (Glover, 2008; Takahashi & Yamanaka, 2006).  
Dr. Yamanaka began working with a strain of mouse known 
as Fbx15 that expresses increased levels of the FBX15 
protein, which is known to be upregulated in pluripotent cells 
(Tokuzawa, et al., 2003).  Using both embryonic and adult 
fibroblasts from these mice, Yamanaka developed a method 
to create cells with characteristics nearly identical to ESCs 
(Takahashi & Yamanaka, 2006).  These cells are known as 
induced pluripotent stem (iPS) cells.  Yamanaka was also 
successful in creating iPS cells from mouse liver and 
stomach cells demonstrating that it is possible to induce 
many types of somatic cells to be pluripotent (Aoi, et al., 
2008).  Finally, Yamanaka applied his methods to a human 
cell model in 2007 (Takahashi, et al.).  While it would seem 
that Yamanaka’s findings would immediately catapult iPS 
cell research into clinical research, there were some 
complications. 
 The iPS cells originally created by Takahashi and 
Yamanaka were not capable of generating chimeric mice 
while naturally pluripotent cells are (2006).  To address this, 
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Yamanaka used a mouse strain that expressed increased 
levels of the Nanog gene – another gene related to 
pluripotency – rather than Fbx15 (Okita, Ichisaka, & 
Yamanaka, 2007).  These iPS cells could generate 
chimeras, but the chimeras had an increased probability of 
developing cancer (Okita, Ichisaka, & Yamanaka, 2007).  
These increased incidents of cancer were related to one of 
the four factors being introduced into the cells: c-Myc (Okita, 
Ichisaka, & Yamanaka).  Therefore, an attempt was made to 
create iPS cells without c-Myc.  Nakagawa, et al. reported 
the successful generation of iPS cells without c-Myc though 
these cells grew at a slower rate (2007).  Current research 
with iPS cells is continually eliminating problems such as 
these and refining Yamanaka’s technique.  Despite any 
slight imperfections remaining in the process of generating 
iPS cells, researchers have already made extensive 
progress using iPS cells for disease research and treatment. 
 Recent studies using iPS cells report results that 
are promising for the clinical application of iPS cells.  Not 
only are iPS cells useful as human disease and gene 
therapy models but they are also sources of patient-specific 
cells that can be easily manipulated (Raya, et al., 2009).  
Current applications of iPS cells are the treatment of 
cardiovascular and hematological ailments, type 1 diabetes, 
and a range of neurological disorders. Researchers have 
isolated somatic cells from patients suffering from each of 
these diseases and created iPS cells either for therapeutic 
applications or to model the specific diseases.  Furthermore, 
tissues generated from iPS cells will be specific to the 
recipient and therefore eliminate the risk of graft rejection 
(Nelson, et al., 2009).   
 
How to Create Induced Pluripotent Stem Cells 
In their 2006 Cell article, Takahashi and Yamanaka describe 
the method used to develop the first iPS cells.  They began 
with a strain of mice known as Fbx15.  These mice were 
genetically engineered to over-express the FBX15 protein.  
FBX15 expression is generally upregulated in ESCs and 
other pluripotent cells (Tokuzawa, et al., 2003).  To allow  
 
  
Figure 1.  A morphological comparison of ESCs, MEFs, and iPS cells from MEFs and TTFs. (A) Embryonic stem cells; (B) Embryonic fibroblasts 
(MEFs) from Fbx15βgeo/βgeo mice; (C) iPS cells generated from MEFs using 10 pluripotency genes; (D) iPS cells generated from adult tail tip fibroblasts 
(TTFs) using four pluripotency genes; (E) iPS cells generated from MEFs using three pluripotency genes. Bars are equal to 200 µm (a composite of 
figures from Takahashi & Yamanaka, 2006).   
 
 
antibiotic selection as a determinant of gene expression, 
Takahashi and Yamanaka inserted a βgeo cassette next to 
the Fbx15 gene by homologous recombination (2006).  βgeo 
causes cells to be resistant to antibiotics as well as express 
β-galactosidase, which can be easily located with staining 
(Tokuzawa, et al., 2003).  Therefore, when cells from these 
mice were cultured on a medium containing an antibiotic, 
G418, persisting cell colonies were both antibiotic resistant 
and pluripotent.  From these mice, the authors utilized both 
embryonic (MEFs) and adult tail tip fibroblasts (TTFs) for 
experimentation. 
 From previous work conducted by other scientists, 
Takahashi and Yamanaka knew of 24 genes that are closely 
related to pluripotency.  All of these genes were either 
upregulated or expressed solely in ESCs (Takahashi & 
Yamanaka, 2006).  The authors initially introduced all 24 of 
these genes into MEFs using retroviral transduction and 
found that they were able to generate cell colonies on their 
G418 medium (Takahashi & Yamanaka, 2006).  However, 
the authors were not convinced that all 24 genes were 
necessary to reprogram their fibroblasts into pluripotent 
cells.  Through a series of experiments in which one of the 
24 genes was absent during retroviral transduction at a time, 
four were identified that were required for cell colony 
formation.  These four genes were Oct3/4, Sox2, Klf4, and c-
Myc (Takahashi & Yamanaka, 2006).  Once again using 
iPS-TTFgfp4 
B A 
C E D 
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retroviral transduction, these four factors were then 
introduced into Fbx15βgeo/βgeo TTFs that also expressed green 
florescent protein (GFP) and again, G418 resistant cell 
colonies formed (Takahashi & Yamanaka, 2006).  When 
made to express these four genes, both MEFs and TTFs 
exhibited characteristics very similar to ESCs.   
 Though the induced pluripotent (iPS) cells 
Takahashi and Yamanaka had created expressed Fbx15, 
the authors wanted to ensure that the cells had the 
characteristics similar to naturally occurring pluripotent cells.  
The first criterion for a pluripotent cell is a rounded, smooth 
morphology as seen in ESCs.  As shown in figure 1, iPS 
cells generated from MEFs and TTFs using 10 or four of the 
identified genes had morphology similar to ESCs (Figures 
1A, 1C, & 1D; Takahashi & Yamanaka, 2006).  However, cell 
colonies created from MEFs using only three of the 
pluripotency genes had strikingly different morphology 
(Figure 1E).  These cells exhibited rough surfaces and 
edges and were not considered pluripotent (Takahashi & 
Yamanaka, 2006). 
 The second characteristic of pluripotent cells that 
Takahashi and Yamanaka looked for in their iPS cells was 
the ability to form teratomas containing tissue types from all 
three germ layers.  To test this, the authors microinjected 
iPS cells from GFP expressing TTFs into Fbx15βgeo/βgeo 
blastocysts then allowed them to develop into mature mice 
(Takahashi & Yamanaka, 2006).  From these mice the 
authors took tissue samples and stained them with eosin 
and an anti-GFP antibody.  As shown in figure 2, tissue 
samples were taken from the heart, gastrointestinal tract, 
liver, gonad, neural tube, and skin of the mature mice and 
GFP-positive cells can be seen in each sample (Takahashi & 
Yamanaka, 2006).  Though these mice did have iPS cells 
incorporated into tissues from all three germ layers, they 
were not able to produce chimeric pups (Takahashi &  
 
 
Figure 2. Tissue samples taken from mature mice generated from 
Fbx15βgeo/βgeo blastocysts microinjected with iPS cells made from 
TTFs expressing GFP, Oct3/4, Sox2, Klf4, and c-Myc.  All cells were 
stained with eosin (blue) while iPS cells were stained with an anti-
GFP antibody (brown; Takahashi & Yamanaka, 2006).   
 
Yamanaka, 2006).  While this fault does not indicate that the 
iPS cells are not truly pluripotent, it does suggest that 
nuclear reprogramming was not complete (Yamanaka, 
2009). 
Finally, Takahashi and Yamanaka compared gene 
expression in iPS cells to ESCs.  Other than the four factors 
the authors introduced to create the iPS cells, expression of 
other known pluripotent cell markers such as Nanog, ERas, 
and p53 was also evaluated.  Figure 3 shows that the levels 
of Oct3/4, Sox2, Klf4, and c-Myc protein expression are 
similar to those in ESCs as expected.  However, there is 
variation between iPS cell types and ESCs in expression of 
Nanog, ERas, and p53.  The significance of this variation 
has not yet been addressed though later studies were able 
to generate iPS cells with gene expression more similar to 
ESCs (Nakagawa, et al., 2007). 
 
 
Figure 3. Southern blot comparing protein expression in iPS cells 
from MEFs using either four (iPS-MEF4-7) or 10 (iPS-MEF10-6) 
pluripotency genes, iPS cells from TTFs using four pluripotency 
genes (iPSTTFgfp4-3 and iPS-TTFgfp4-7), ESCs, and MEFs.  β actin 
serves as a loading control (fig. 7A from Takahashi & Yamanaka, 
2006). 
 
Despite these discrepancies, not all iPS cells 
generated had a different gene expression profile from 
ESCs.  Nanog was not down regulated in all of the iPS cells, 
only iPS-MEF4-7, iPS-TTFgfp4-3, and iPS-TTFgfp4-7 cells.  
Similarly, ERas was only down-regulated in iPS-MEF4-7 
cells and p53 only in iPS-MEF10-6 cells.  These differences 
may have a number of variables affecting them.  However, 
though they had slight gene expression differences, the iPS 
cells created by Takahashi and Yamanaka in 2006 are 
considered as the first pluripotent cells generated from 
somatic cells without ESCs. 
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Figure 4.  Distribution of DNA within various tissues in chimeric mice generated from Nanog iPS cells.  Three clone (20D17, 38C2, and 38D2) 
expressed varying levels of maternal (C57BL/6, upper bands) and iPS (DBA, lower bands) DNA in each tissue type (figure 6a from Okita, Ichisaka, & 
Yamanaka, 2007). 
 
Now that Takahashi and Yamanaka had proven 
that iPS cells could be generated from somatic cells, further 
research concerning their inability to form chimeras was 
necessary.  To solve this problem, mice over-expressing 
Nanog rather than Fbx15 were used to create iPS cells 
(Okita, Ichisaka, & Yamanaka, 2007).  Fbx15 expression is 
upregulated in ESCs but their pluripotent nature is not 
dependent upon it and therefore neither was iPS cell 
formation (Yamanaka, 2009; Glover, 2008).  Nanog null 
cells, however, do not maintain their pluripotency (Okita, 
Ichisaka, & Yamanaka, 2007).  Therefore, iPS cells from 
mice over-expressing Nanog were used in an attempt to 
create chimeric mice (see appendix C for method).  As can 
be seen in figure 4, various tissues from these mice 
expressed both iPS cell DNA and maternal DNA.   
 As reported by Okita, Ichisaka, and Yamanaka, 
the level of chimerism varied from 10-90% (2007).  This 
variation can easily be seen in the band size differences in 
figure 4.  While the spleen, kidney, and gonad of clone 
20D17 contained mostly maternal DNA, the brain had mostly 
maternal DNA.  Conversely, clone 38D2 had mostly 
maternal DNA in the brain, lung, heart, and spleen and 
mostly iPS DNA in the liver.  The authors concluded that 
most, but not all, of their Nanog iPS cells could produce 
competent chimeras (Okita, Ichisaka, & Yamanaka, 2007).   
When male 20D17 clones – those with the highest levels of 
iPS DNA in the gonad (fig. 4) – were crossed with C57BL/6 
females, coat color and PCR confirmed germline 
transmission of the Nanog-iPS-20D17 DNA (Okita, Ichisaka, 
& Yamanaka, 2007).  These methods, therefore, produced 
iPS cells that had undergone more complete nuclear 
programming than those of Takahashi and Yamanaka in 
2006. 
 An issue that arose once chimeric mice were 
created was that approximately 20% of the chimeric mice 
created using Nanog-iPS cells developed tumors (Glover, 
2008; Okita, Ichisaka, & Yamanaka, 2007).  While this is a 
trait shared by chimeras produced by ESCs (Nelson, et al., 
2009), it creates obvious problems if iPS cells are to be used 
to generate tissues for transplantation.  Okita, Ichisaka, and 
Yamanaka reported that tumor formation in the chimeric 
mice they created seemed to correlate with the expression of 
one of their four factors: c-Myc (2007).  Therefore, though it 
was originally thought that all four factors were necessary to 
generate iPS cells (Takahashi & Yamanaka, 2006), 
Yamanaka and his lab now focused on creating iPS cells 
without c-Myc.   
 Chimeric mice were created as described in 
appendix C either with or without c-Myc expression in and 
Nanog iPS mouse strains (Nakagawa, et al., 2007).  It was 
found that the failed iPS formation without c-Myc expression 
reported by Takahashi & Yamanaka was unsuccessful 
because drug selection was initiated too early (Nakagawa, et 
al., 2007).  Nanog iPS cells expressing only three factors – 
Sox2, Oct3/4, and Klf4 but not c-Myc – treated with 
puromycin after 14 days of culture were able to generate iPS 
colonies while those treated with puromycin at 7 days were 
not (Nakagawa, et al., 2007).  Also, when tumorigenicity of 
Myc- and Myc+ iPS cells was compared, Myc- iPS cells did 
not cause tumors to form in chimeric mice whereas Myc+ 
iPS cells did (Nakagawa, et al., 2007).  Furthermore, as 
depicted in figure 5, expression of ESC markers in these 
cells is more similar to ESC expression than the iPS cells 
generated by Takahashi and Yamanaka in 2006 (Nakagawa, 
et al., 2007).  The gel presented in figure 5 is markedly 
different from that in figure 3, which shows variation of ESC 
marker expression in Fbx15 iPS cells. 
Therefore, iPS cells generated from Nanog knock-
in mice without the over-expression of c-Myc were able to 
produce adult chimeras, did not cause tumor formation in 
those chimeras, and had gene expression levels of ESC 
markers that are equal to those in ESCs (Nakagawa, et al., 
2007).  The use of Nanog mice rather than Fbx15 mice and 
the exclusion of c-Myc from retroviral transduction solved all 
of the issues Takahashi and Yamanaka encountered with 
iPS cells in 2006.  
 
Clinical Applications of iPS Cells 
Research using mouse iPS cells for cell treatment therapies 
and disease modeling have been very successful.  
Specifically, iPS cell differentiation into cardiovascular and 
hematopoietic cells from anemic and hemophilic mice has 
been achieved and applied to disease treatment.  Diabetes 
research with iPS cells has resulted in mouse insulin- 
producing cells and islet cluster formation, which have 
promising applications for treatment of type 1 and juvenile 
diabetes.  Though all of these findings were reported with 
mouse models rather than human cells, they suggest that 
iPS cells have great potentials for treating human diseases.   
The ability of iPS cells to differentiate into 
hematopoietic cells has been described within the last year 
 
 
	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.  RT-PCR results from ESCs, Nanog iPS cells without 
exogenous Myc expression (clones 142B-6 & 142B-12), and Nanog 
MEFs were run through gel electrophoresis.  Both Nanog iPS cell 
clones exhibited similar expressions of the five ESC marker genes 
(Nanog, Rex1, ECAT1, and ERas).  G3PDH and G3PDH RT- served 
as positive and negative loading controls, respectively (figure 2b from 
Nakagawa, et al., 2007). 
 
 
 (Hanna, et al., 2009; Raya, et al., 2009; Schenke-Layland, 
et al., 2008).  Using the techniques originally described by 
Yamanaka and Takahashi to generate iPS cells (appendix 
B), disease and patient specific cells for the treatment 
Fanconi anemia (FA) and sickle cell anemia have been 
created.   
 iPS cells generated from mouse model sickle cell 
anemia and FA cells were treated with wild type human 
globulin genes (appendix D) or lentiviruses known to correct 
the FA genotype (appendix E), respectively (Hanna, et al., 
2009; Raya, et al., 2009).  These genetically corrected iPS 
cells were then exposed to differentiating protocols, which 
induced the formation of hematopoietic progenitor cells 
(Appendices D & E).  While the FA hematopoietic progenitor 
cells created were not used to treat FA, the method used to  
develop them is ideal for generating disease-free  
hematopoietic cells for future disease treatment (Raya, et al., 
2009).  As can be seen in figure 6, down-regulation of the 
lentiviruses used to correct the FA mutation by short hairpin 
RNAs (siRNAs) caused a significant decrease in cell 
proliferation as determined by mitotic index percentage 
(Raya, et al., 2009).  When scrambled (control) siRNA was 
used, there was no decrease in cell proliferation.  However, 
when siRNA specific to the correctional FA lentivirus were 
used, there was a marked decrease in cell proliferation 
regardless of culturing in diepoxybutane (figure 6). 
The differentiated cells created in the sickle cell 
anemia mouse models, however, were used for disease 
treatment (Hanna, et al., 2009).  Disease corrected iPS cells 
from sickle cell anemia mouse models were transplanted 
into irradiated male mice homologous for sickle cell anemia.  
Unhindered engraftment was observed for up to 12 weeks 
after treatment and, as can be seen in figure 7, treatment of 
sickle cell model mice with the genetically corrected iPS cells 
inhibited the sickle cell phenotype (Hanna, et al., 2009).   
 
 
 
 
Figure 6.  Comparison of cell proliferation as determined by mitotic 
index when disease corrected FA iPS cells were treated with 
scrambled (control) siRNA or FANCA specific siRNAs and cultured in 
the presence of diepoxybutane (figure 4e from Raya, et al., 2009). 
 
Similar to the studies of anemia, differentiated iPS cells have 
also been used in diabetes research; however, iPS cells 
have yet to be applied to diabetes treatment or therapy.  In 
two independent studies, human iPS (hiPS) cells were used 
to create insulin-secreting cells that phenotypically resemble 
those of non-diabetics (Maehr, et al., 2009; Tateishi, et al., 
2008).  Human skin fibroblasts were made to express either 
three of the pluripotency factors found by Takahashi and 
Yamanaka using retroviruses (without c-Myc; Maehr, et al., 
2009) or with all four factors (Tateishi, et al., 2008).  Insulin-
secreting cells were then differentiated from these cells 
using a step-wise differentiation protocol shown in figure 8 
(discussed in more detail in appendix F).   
Insulin-secreting islet clusters were identified by 
morphological similarities to pancreatic cell lineages as well 
as gene expression and mRNA levels at stage 4 of 
differentiation (Maehr, 2009; Tateishi, et al., 2008).  The 
ability of these cells to produce insulin was determined by 
exposing the cells to varying concentrations of glucose using  
 
Figure 8. The step-wise differentiation of hiPS cells from HEF-1 skin 
fibroblasts into insulin secreting cells.  The differentiation factors 
shown here were specific to the methods of Tateishi, et al., 2008 
(figure 3A from Tateishi, et al., 2008). 
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C-peptide enzyme-linked immunoabsorbant assays (Maehr, 
et al., 2009; Tateishi, et al., 2008).  While exposure to 
glucose in both studies caused the differentiated hiPS cells 
to produce insulin, those created by Tateishi, et al. only did 
so when exposed to glucose concentrations of 40 mM 
(2008).  Insulin-producing cells from the study by Maehr, et 
al. were proportionally responsive to concentrations of 
glucose between 2.5 mM and 20 mM as can be seen in 
figure 9 (2009).   
 The discrepancy between these two findings could 
be due to the types of cells and method used to generate 
hiPS cells or the protocol for differentiation into insulin 
producing cells.  Further research is necessary to determine 
the cause.  However, these studies show that it is possible to 
generate human iPS cells and apply them to regenerative 
medicine.  With continued research, cells similar to those 
created in these two studies may be used as therapeutic 
treatment for type 1 and juvenile diabetics. 
 
Future iPS Cell Research 
Induced pluripotent stem (iPS) cells exhibit characteristics 
that are nearly identical to embryonic stem cells (ESCs).  
ESCs and iPS cells have rounded morphologies, specific  
 
 
 
 
 
gene expression, and teratoma formation abilities (Okita, 
Ichisaka, & Yamanaka, 2007; Nakagawa, et al., 2007; 
Takahashi and Yamanaka, 2006).  The similar gene 
expression of both types of cells allows them to divide 
indefinitely and differentiate into any cell type meaning that 
they are pluripotent.  Due to their pluripotency, ESCs and 
iPS cells have unfathomable applications in regenerative 
medicine, disease modeling, and drug therapy testing.  
However, because ESCs are not patient or case specific, 
their applications are limited. 
 ESCs are harvested from unused in vitro 
fertilization embryos; therefore, their use in generating 
tissues and/or cells for transplantation is limited by the risk of 
host rejection (Yamanaka, 2009).  Furthermore, because 
they have nonspecific genotypes, they are not applicable to 
case-by-case disease modeling or drug therapy screening.  
iPS cells generated from patient somatic cells, on the other 
hand, share the patient’s genetic background, which 
eliminates the risk of host graft rejection.  Similarly, due to 
this shared genetic background, iPS cells can accurately 
model diseases as they affect different individuals.  This will 
help researchers better understand the range of disease 
phenotypes expressed by affected individuals.  However, 
more research is necessary before iPS cells can be used in 
medical clinics. 
 Firstly, the exact mechanisms that regulate both 
pluripotency induction and cell differentiation need to be 
defined.  This will allow complete characterization of iPS 
cells and the causes of their pluripotency.  It will also answer 
the question as to whether or not c-Myc is necessary to 
create iPS cells.  The over-expression of this gene is 
potentially tumorigenic, though not all reports agree.  
Nakagawa, et al. reported successful iPS cell formation 
using only Oct3/4, Sox2, and Klf4 (2007).  Though 
pluripotency induction took place at a slower rate in this 
model, the iPS cells generated had expression profiles more 
similar to ESCs than iPS cells created with all four 
pluripotency factors (compare figures 3 and 5; Nakagawa, et 
al., 2007).  Furthermore, other laboratories have been able 
to produce iPS cells with retroviral transduction of Nanog 
and Lin28 genes in place of Klf4 and Sox2 (Yu, et al., 2009; 
Glover, 2008).  This also suggests that c-Myc is not 
necessary to induce pluripotency in somatic cells.  Answers 
to questions such as this will help human iPS (hiPS) cell 
research.  While Takahashi, et al. have described a method 
to create hiPS cells, the procedure had to be altered from 
that used in mouse models due to the inefficiency of 
transgene induction (2007).  Furthermore, the exclusion of c-
Myc from the iPS cell retroviral transduction cocktail was  
 
 
 
 
 
 
 
 
Figure 9. Graphical analysis of insulin production from three 
differentiated type 1 diabetes iPS cell lines (DiPS H2.1, DiPS H2.4, 
and DiPS H1.5) compared to an ESC line (HUES 8).  C-peptide 
production correlates with insulin production as determined by C-
peptide enzyme-linked immunoabsorbant assays.  Bars represent 
standard error (figure 5C from Maehr, et al., 2009). 
 
Figure 7. A comparison of sickle cell phenotypes in heterozygous (control) and treated and untreated homozygous mice.  Arrows indicate 
presence of sickle shaped erythrocytes (figure 3D from Hanna, et al., 2009). 
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found to significantly decrease the efficiency of hiPS cell 
formation (Nakagawa, et al., 2007).  This is a serious issue 
for regenerative medicine involving hiPS cells in light of the 
potential tumorigenicity of c-Myc (Maehr, et al., 2009; 
Nakagawa, et al., 2007). 
 Once the mechanisms through which nuclear 
reprogramming occurs in iPS cells is understood, induction 
methods may be found that do not include retroviral 
transgenes.  While lentiviruses that can be excised are an 
intriguing alternative, they do not circumvent the fact that 
viral vectors are inserted into the genome of the cells.  
These insertions may lead to mutations that affect both the 
formation, function, and tumor formation of iPS cells (Fusaki, 
et al., 2009; Yu, et al., 2009). 
 Finally, once questions concerning the 
mechanisms of pluripotency induction are understood and 
alternate methods without viral vectors are specified, iPS 
cells can be applied to generating whole organs for 
transplantation.  Currently, iPS cell research has only been 
able to generate specific cell types.  However, new reports 
suggest that whole organs from iPS cells are not far in the 
future.  Viczian, et al. (2009) and Carr, et al. (2009) 
individually report the development of retinal precursors from 
iPS cells treated with specific differentiation factors.  
Similarly, cardiomyocyte-like cells have been created from 
iPS cells that beat spontaneously (Mauritz, et al., 2009; 
Narazaki, et al., 2009).  Retinal, cardiovascular, and β cell 
like precursors have all been generated using either mouse  
or human iPS cells (Viczian, et al., 2009; Carr, et a., 2009; 
Mauritz, et al., 2009; Narazaki, et al., 2009; Maehr, et al., 
2009).  The ability of iPS cells to differentiate into such a 
range of tissue types suggest that generating of whole 
organs from iPS cells is feasible. 
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Appendix 
 
A. Abbreviations 
  
ESC: embryonic stem cell 
FA: Fanconi anemia 
GFP: green florescent protein 
HDF: human dermal fibroblasts 
HDF-Slc7a1: human dermal fibroblasts expressing the 
mouse retroviral receptor  
hiPS: human induced pluripotent stem cells 
iPS: induced pluripotent stem cells 
MEF: mouse embryonic fibroblast  
PD: Parkinson’s disease 
TTF: tail tip fibroblasts from adult mice  
  
B. Method for iPS cell generation (from Takahashi & 
Yamanaka, 2006) 
Homologous recombination was used to make Fbx15 mice 
express a βgeo cassette, which caused them to be resistant 
to antibiotics.  Oct3/4, Sox2, Klf4, and c-Myc were 
introduced into Fbx15βgeo/βgeo MEFs and TTFs through 
retroviral transduction.  Plat-E cells inoculated with the 
appropriate plasmid DNA were used to cultivate the 
transgenes.  Cell colonies were cultured on media mixed 
with the antibiotic G418.  iPS cells that produced colonies on 
the G418 media were considered to be pluripotent 
(assuming expression of Fbx15 along with the βgeo 
cassette).   
 
C. Method for Nanog iPS chimeras (from Okita, Ichisaka, 
& Yamanaka, 2007) 
Nanog reporter mice were created by introducing a bacterial 
artificial chromosome with the mouse Nanog gene at the 
center into ESCs.  Through homologous recombination, GFP 
and puromycin resistance (Puro) genes were also inserted.  
GFP expression was observed in all treated cells able to 
colonize in the presence of puromycin until the cells became 
differentiated.  MEFs were isolated from these Nanog-GFP-
Puro mice and used for experimentation.  The MEFs were 
made to express Oct3/4, Klf4, Sox2, and c-Myc through 
retroviral transduction (see appendix B) and expression of 
the construct was selected for by puromycin exposure.  The 
authors microinjected male Nanog iPS cells into C57BL/6 
blastocysts and transplanted the blastocysts into the uteri of 
female DBA pseudo-pregnant mice to generate germline 
chimeras.  Chimera formation was confirmed by analyses of 
maternal and paternal DNA expression and coat color. 
 
D. Protocol for differentiation of sickle cell anemia 
mouse model iPS cells into hematopoietic precursors 
A humanized mouse model of sickle cell anemia was 
generated by substituting mouse α-globulins with human α-
globulins and mouse β-globulins with human sickle cell β-
globulins (hβS).  iPS cells from homozygous hβS mouse 
somatic cells were generated as described in appendix B.  
Selected hβS/hβS iPS cells were then eletroporated with a 
genetic construct containing wild type human β-globulin 
genes to correct the sickle cell mutation.  These genetically 
corrected iPS cells were then treated with a Moloney virus 
containing genes for GFP (for visualization purposes) and 
HoxB4 (a homeobox protein known to cause hematopoietic 
differentiation in ESCs).  Cells with this treatment expressed 
markers for early hematopoietic progenitor, myeloid, and 
erythroid cells, which confirmed their differentiation.   
 
E. Differentiation protocol for differentiating FA mouse 
model iPS cells into hematopoietic precursors (from 
Raya, et al., 2009) 
Mouse model FA iPS cells were generated as described in 
appendix B.  They were then treated with lentiviruses 
containing either FANCA or FANCD2 and cultured in 
diepoxybutane (DEB).  Both viral vectors correct the FA 
phenotype but do not affect ESC molecular markers, ESC-
like gene expression, teratoma formation, or karyotype 
abnormalities of the iPS cells.  Knocking down expression of 
FANCA vector expression using siRNA confirmed (see figure 
6) that the FA genetic pathway was reintroduced and the 
mutation common to FA sufferers corrected.  Decreased 
levels of FANCA expression (70% down-regulation) inhibited 
FA iPS cells from proliferating through one passage.  FA 
corrected iPS cells (without siRNA) were co-cultured with 
0P9 stromal cells and treated with hematopoietic cytokines 
for up to 12 days.  CD34+ cells were detectable after 5 days 
of culturing and CD45+ cells after 10 days of culturing.  When 
isolated after 12 days of culture, CD34+ cells produced large 
erythroid and myeloid colonies. 
 
F. Protocol for hiPS cell differentiation into insulin-
secreting cells (from Maehr, et al., 2009 and Tateishi, et 
al., 2008) 
In Tateishi, et al., HEF-1 strain human skin fibroblasts were 
made into hiPS using Oct3/4, Sox2, Klf4, and c-Myc 
retroviral vectors.  These cells were then cultured step-wise 
with the following compounds as depicted in figure 8.  Activin 
A and sodium butyrate treatment caused undifferentiated 
cells to become endodermic.  Treatment with EGF, bFGF, 
and Noggin differentiated the cells into pancreatic cells.  
Continued culture with Noggin and EGF caused 
exocrine/endocrine differentiation.  And finally, exposure to 53	  
 
 
	  
IGFII and Nicotinamide caused the cells to differentiate into 
insulin producing cells.   
 Maehr, et al. used a similar though slightly 
different protocol to develop insulin-producing cells from 
hiPS cells.  Fibroblasts were isolated from skin biopsies of 
type 1 diabetes patients and made into hiPS cells by 
retroviral introduction of only Oct3/4, Sox2, and Klf4.  To 
differentiate these cells into insulin-producing cells, the 
authors first exposed the cells to WNT3A and Activin A to 
form endodermic cells.  This was followed by FGF10 and 
cyclopamine treatment to form gut tube endoderm, and a 
combination of FGF10, cyclopamine, retinoic acid, and 
Indolactam V caused differentiation into pancreatic 
progenitors.  In both experiments, each step of differentiation 
was confirmed by analysis of specific cell marker 
expressions. 
 
Note: Eukaryon is published by students at Lake Forest 
College, who are solely responsible for its content. The 
views expressed in Eukaryon do not necessarily reflect 
those of the College. Articles published within Eukaryon 
should not be cited in bibliographies. Material contained 
herein should be treated as personal communication and 
should be cited as such only with the consent of the author. 
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